Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | STAT3 | P40763 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.46 |
| ▸ | NSD2 | O96028 | 5/20 | 0.38 |
| ▸ | TDP2 | O95551 | 4/20 | 0.38 |
| ▸ | APAF1 | O14727 | 3/20 | 0.38 |
| ▸ | HKDC1 | Q2TB90 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | ATG4B | Q9Y4P1 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | GALK1 | P51570 | 2/20 | 0.36 |
| ▸ | BLM | P54132 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triaziquone SCHEMBL8303 | 0.86 | DNMT1 (0.48) | MAPTHTTTP53STAT3SMN1; SMN2 | |
| Triaziquone SCHEMBL7783197 | 0.85 | MAPT (0.46) | MAPTHTTTP53STAT3SMN1; SMN2 | |
| Triaziquone SCHEMBL149876 | 0.85 | MAPT (0.46) | MAPTHTTTP53STAT3SMN1; SMN2 | |
| Triaziquone SCHEMBL5054475 | 0.84 | DNMT1 (0.47) | MAPTHTTTP53STAT3SMN1; SMN2 | |
| Triaziquone SCHEMBL1538515 | 0.84 | DNMT1 (0.47) | MAPTHTTTP53STAT3SMN1; SMN2 | |
| Triaziquone SCHEMBL3101456 | 0.84 | DNMT1 (0.47) | MAPTHTTTP53STAT3SMN1; SMN2 | |
| Triaziquone SCHEMBL8993238 | 0.84 | DNMT1 (0.47) | MAPTHTTTP53STAT3SMN1; SMN2 | |
| Triaziquone SCHEMBL6000230 | 0.84 | DNMT1 (0.47) | MAPTHTTTP53STAT3SMN1; SMN2 | |
| Triaziquone SCHEMBL8482641 | 0.84 | DNMT1 (0.47) | MAPTHTTTP53STAT3SMN1; SMN2 | |
| Triaziquone SCHEMBL7738777 | 0.84 | DNMT1 (0.47) | MAPTHTTTP53STAT3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070203109-A1 | Compounds And Compositions For Treatment Of Cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-08-30 | — | — | US | disclosed |
| US-6156744-A | DT-diaphorase directed anti-tumor agents | CANCER RESEARCH CAMPAIGN TECH (LONDON) | 2000-12-05 | — | — | US | disclosed |
| EP-0993304-A1 | PHARMACEUTICAL COMPOSITION HAVING ENHANCED ANTITUMOR ACTIVITY AND/OR REDUCED SIDE EFFECTS, CONTAINING AN ANTITUMOR AGENT AND AN HYDROXAMIC ACID DERIVATIVE | N-Gene Research Laboratories Inc. (US) | 2000-04-19 | — | — | EP | disclosed |
| WO-1998058676-A1 | PHARMACEUTICAL COMPOSITION HAVING ENHANCED ANTITUMOR ACTIVITY AND/OR REDUCED SIDE EFFECTS, CONTAINING AN ANTITUMOR AGENT AND AN HYDROXAMIC ACID DERIVATIVE | N-GENE RESEARCH LABORATORIES INC. (US) | 1998-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203109-A1 | Compounds And Compositions For Treatment Of Cancer | RB1, EHMT1, TP53 | MAPT 4760/4885HTT 1378/4885TP53 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.